Market overview
The global organ transplantation market share, as per the study conducted by Market Research Future (MRFR), is expected to reach at a compound annual growth rate of 8.33% during the forecast period of 2024 to 2032.
Organ transplantation involves the process of replacing the diseased and damaged organ of an individual with a healthy organ. It is one of the great advancements in the modern healthcare landscape. This medical procedure has evolved and advanced over the years, thereby enhancing the clinical effectivity of the same. Organs are donated by either some living donor or it is harvested from the brain-dead organ donors. Dysfunction of the organ caused due to diseases like cancer, severe injuries, failure of the organ, and due to genetic disorders require the need for organ transplant procedures. Organs such as heart, liver, lungs, kidney, and many more can be transplanted through this procedure.
The transplantation process is carried out primarily with the brain-dead patient whose other organs are in a healthy state and can be used to save the life of another person. An increasing number of organ transplantation surgeries undertaken globally is one of the major drivers of the future of organ transplants market. Increasing prevalence of chronic diseases, advancements in technology, changing lifestyle of individuals, and the rising aging population are some of the other key factors influencing the growth of the global market.
Competitive Landscape
The global organ transplantation market players of various notable players TransMedic, Inc. (US), Transonic (US), Novartis International AG (Switzerland), OrganOX Limited (UK), F. Hoffmann-La Roche Ltd. (Switzerland), Terumo Medical Corporation (US), Preservation Solutions, Inc. (US), Transplant Biomedical (UK), Accord Healthcare GmbH (Spain), Astellas Pharma, Inc (Japan), Pfizer, Inc. (US), Veloxis Pharmaceuticals A/S (Denmark), Bio Med Pvt. Ltd. (US), GlaxoSmithKline Plc. (UK), Sanofi (France), and others.
Market Segmentation
The global organ transplantation market outlook segmentation is done as per the following dynamics: type. End-users, products, and treatment.
By type, the market comprises of lungs, heart, liver, kidney, and others.
By products, the market segments into tissue products, organ preservation solutions, transplant diagnostics, and others.
By type of treatment, the market includes immunosuppressant, analgesic, and other. Immunosuppressant is narrowed down into mTOR inhibitor, calcineurin inhibitors, steroids, antiproliferative agents, and other. Whereas calcineurin inhibitors are divided into tacrolimus and cyclosporine. And, mTOR inhibitor is broken down into sirolimus and everolimus.
By type of transplant, the market includes allograft, xenograft, autograft, allotransplantation, xenotransplantation, and others.
By end users, the market comprises transplant centers, hospitals, and others.
Regional Analysis
The regional segmentation of the organ transplantation market insight covers the following regions: Europe, Americas, Asia Pacific, and the Middle East and Africa.
America holds the largest share of the market in the global standings of organ transplantation. This is due to the increasing prevalence of chronic diseases. Other key factors influencing the growth of the market in this region are the rising aging population, an increase in the number of organ transplantation cases, and striking developments in technology.
Europe stands second in the global organ transplantation market due to various essential factors or drivers. The regional market is driven by the developed infrastructure, encouragement for the emergence of new organizations, and increasing expenditures on healthcare.
Asia Pacific is expected to grow at a notable pace in the near future and cement its position as one of the key regions in the global organ transplantation market. Factors such as fast-paced development in the healthcare industry, presence of a huge patient population pool, and the availability of skilled professionals are the major growth drivers of the market. However, in the Middle East and Africa region, the poor economical condition coupled with the limited growth of the healthcare sector is expected to be responsible for the meagre growth of the region.
Related Reports-
Comments (0)